Citigroup’s Centessa Pharmaceuticals CNTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-74,276
| Closed | -$2.95M | – | 5797 |
|
|
2026
Q1 | $2.95M | Buy |
74,276
+71,585
| +2,660% | +$1.83M | ﹤0.01% | 2392 |
|
|
2025
Q4 | $67.3K | Buy |
2,691
+847
| +46% | +$21.5K | ﹤0.01% | 4480 |
|
|
2025
Q3 | $44.7K | Buy |
1,844
+23
| +1% | +$409 | ﹤0.01% | 4537 |
|
|
2025
Q2 | $23.9K | Buy |
1,821
+491
| +37% | +$6.22K | ﹤0.01% | 5034 |
|
|
2025
Q1 | $19.1K | Buy |
1,330
+151
| +13% | +$2.47K | ﹤0.01% | 5103 |
|
|
2024
Q4 | $19.7K | Sell |
1,179
-12,915
| -92% | -$214K | ﹤0.01% | 5269 |
|
|
2024
Q3 | $225K | Buy |
14,094
+12,866
| +1,048% | +$158K | ﹤0.01% | 4259 |
|
|
2024
Q2 | $11.1K | Buy |
1,228
+1,024
| +502% | +$9.71K | ﹤0.01% | 5117 |
|
|
2024
Q1 | $2.31K | Sell |
204
-795
| -80% | -$7.53K | ﹤0.01% | 5380 |
|
|
2023
Q4 | $7.95K | Buy |
999
+343
| +52% | +$2.3K | ﹤0.01% | 5250 |
|
|
2023
Q3 | $4.24K | Sell |
656
-239
| -27% | -$1.64K | ﹤0.01% | 4758 |
|
|
2023
Q2 | $5.54K | Buy |
895
+294
| +49% | +$1.4K | ﹤0.01% | 5175 |
|
|
2023
Q1 | $2.31K | Sell |
601
-67
| -10% | -$245 | ﹤0.01% | 5077 |
|
|
2022
Q4 | $2.07K | Hold |
668
| – | – | ﹤0.01% | 5228 |
|
|
2022
Q3 | $3K | Sell |
668
-557
| -45% | -$2.55K | ﹤0.01% | 5370 |
|
|
2022
Q2 | $6K | Buy |
1,225
+314
| +34% | +$2.01K | ﹤0.01% | 5541 |
|
|
2022
Q1 | $8K | Sell |
911
-118
| -11% | -$1.08K | ﹤0.01% | 5630 |
|
|
2021
Q4 | $12K | Buy |
1,029
+820
| +392% | +$11K | ﹤0.01% | 5522 |
|
|
2021
Q3 | $3K | Sell |
209
-882
| -81% | -$18.3K | ﹤0.01% | 5633 |
|
|
2021
Q2 | $24K | Buy |
+1,091
| New | +$25.6K | ﹤0.01% | 5190 |
|
Citigroup's CNTA Position: Q2 2026 in Review
Citigroup sold out of Centessa Pharmaceuticals (CNTA) in Q2 2026, closing a stake of 74,276 shares — an estimated $2.95M sold.
Citigroup first reported a position in CNTA in Q2 2021 and held it in 20 quarters. The position peaked at $2.95M in Q1 2026. 0 funds tracked by Wall St. Rank hold CNTA as of Q2 2026.
- Citigroup reported no remaining Centessa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Citigroup sold 74,276 Centessa Pharmaceuticals shares in Q2 2026, an estimated $2.95M.
- Citigroup first reported a position in Centessa Pharmaceuticals in Q2 2021 and held it in 20 quarters.
- Citigroup's Centessa Pharmaceuticals position peaked at $2.95M in Q1 2026.
- 0 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2026.
Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.